Results 101 to 110 of about 101,889 (202)

Low-Dose Intravenous Methylprednisolone in Remission Induction Therapy for ANCA-Associated Vasculitis. [PDF]

Kidney360, 2023
Floyd L, Morris AD, Shetty A, Brady ME, Ponnusamy A, Warwicker P, Dhaygude A.   +6 more
europepmc   +1 more source

Remission Induction of IgG4-related Membranous Nephropathy with Multitarget Therapy. [PDF]

Intern Med, 2023
Furuto Y, Hashimoto H, Namikawa A, Morikawa T, Shibuya Y.   +4 more
europepmc   +1 more source

A Randomized Controlled Trial Comparing Remission Induction with Modified Multitarget Therapy with Intravenous Cyclophosphamide in Proliferative Lupus Nephritis. [PDF]

Indian J Nephrol, 2023
Pal A, Chaudhury AR, Bhunia A, Bhattacharya K, Chatterjee S, Divyaveer SS, Sircar D, Sen D.   +7 more
europepmc   +1 more source

Remission induction and remission duration with primary radiotherapy in advanced lymphosarcoma [PDF]

Cancer, 1972
openaire   +2 more sources

Comparative Effectiveness of Rituximab- Versus Cyclophosphamide-Based Remission Induction Strategies in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis for the Risk of Kidney Failure and Mortality. [PDF]

Arthritis Rheumatol, 2023
Wallace ZS, Fu X, Cook C, Ahola C, Williams Z, Doliner B, Hanberg JS, Stone JH, Zhang Y, Choi HK.   +9 more
europepmc   +1 more source

Number of Courses of Induction Therapy Independently Predicts Outcome after Allogeneic Transplantation for Acute Myeloid Leukemia in First Morphological Remission

, 2015
Whether the number of chemotherapy cycles required to obtain a first morphological remission affects prognosis of patients with acute myeloid leukemia (AML) remains controversial.
Godwin, Colin D., Storer, Barry E., Sorror, Mohamed L., Pagel, John M., Storb, Rainer, Buckley, Sarah A., Walter, Roland B., Sandmaier, Brenda M., Deeg, H. Joachim, Appelbaum, Frederick R.   +9 more
core   +1 more source

Methylprednisolone pulses are associated with faster remission in Giant Cell Arteritis: a multicentre inception cohort study

Arthritis Research & Therapy
Background Despite being the cornerstone of induction therapy in Giant Cell Arteritis (GCA), glucocorticoids (GCs) often fail to achieve sustained disease control and are associated with substantial morbidity, while evidence supporting the broader use of
Román Fernández-Guitián, Ana Royuela, Fernando Tornero-Romero, Andrés González-García, Cristina Ausín-García, Isabel Perales-Fraile, Elena García-Guijarro, Borja de Miguel, Elena Martínez-Robles, Teresa Ramírez-Sanciñena, María Larrea-Gutiérrez, David Lucena López, Rebeca Arenas Hernando, Daniel García-Guadix, Laura Cristina Toma, Sandra Nicás-Jiménez, José María Basauli Felices, Inés Moreno Casado, Víctor Bello, Víctor Moreno-Torres   +19 more
doaj   +1 more source

Costs associated with adverse events from remission induction for children with Acute Lymphoblastic Leukemia (ALL). [PDF]

BMC Health Serv Res, 2022
Mejía-Aranguré E, Reyes-López A, Juárez-Villegas LE, Hernández-Olivares YO, Saucedo-Campos AD, Hernández-Pliego G, Martínez-Valverde S, Barajas-Nava LA, Garduño-Espinosa J.   +8 more
europepmc   +1 more source

Rituximab for Remission Induction and Maintenance in Refractory Systemic Lupus Erythematosus

, 2014
Systemic lupus erythematosus (SLE) is a chronic inflammatory autoimmune disease with high morbidity if untreated. Sometimes, despite aggressive treatments, the disease remains active with cumulative organic damage.
Cañas Dávila, Carlos Alberto, Echeverri, Andrés Felipe   +1 more
core   +1 more source

Investigation of the Clinical Remission Course in Ulcerative Colitis from Tofacitinib Induction to Tapering or Withdrawal in Japanese Patients: A Single-Center Retrospective Study

Inflammatory Intestinal Diseases
Introduction: Tofacitinib (TOF), a Janus kinase inhibitor, has emerged as an innovative treatment option for patients with moderate-to-severe ulcerative colitis (UC).
Miki Koroku, Teppei Omori, Shun Murasugi, Ayumi Ito, Maria Yonezawa, Shinichi Nakamura, Katsutoshi Tokushige, Yousuke Nakai   +7 more
doaj   +1 more source